Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

13.86
EUR
+0.12
(+0.87%)
0.12EPS
130.48P/E
1.73BMarket Cap
Mar 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.42
0.24
0.03
0.11
2.63
4.54
5.17
6.93
8.64
10.66
13.46
20.01
21.96
18.58
Basic EPS, GAAP
-3.31
-3.39
-5.2
-5.49
-0.86
-5.46
-9.71
-7.11
-5.15
-8.03
-5.8
2.47
-7.13
0.14
Free Cash Flow per Basic Share
-2.02
-3.88
-3.65
-5.19
-4.3
-6.84
-7.05
0.32
-5.96
-4.08
-6.37
-3.71
-3.15
1.63
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
6.55
5.99
4.17
6.15
12.18
14.52
10.88
9.6
10.65
4.38
9.17
15.77
10.87
14.26
Tangible Book Value per Share
6.41
5.85
4.03
6
11.96
14.36
10.72
9.43
10.49
4.29
8.85
15.49
10.59
13.98
Basic Weighted Avg Shares
34
40
42
49
59
66
74
78
81
88
92
95
100
105
Sales/Revenue/Turnover
14
10
1
5
155
301
381
540
702
933
1,243
1,902
2,198
1,956
Operating Margin (%)
-634.95
-1,371.21
-17,572.55
-4,873.31
-92.64
-114.15
-137.15
-104.46
-64.07
-57.47
-21.54
11.47
-29.92
-0.43
Depreciation Expense
1
4
5
6
8
12
25
27
38
42
44
38
45
32
Net Income, GAAP
-112
-136
-220
-267
-51
-362
-715
-554
-419
-703
-536
235
-713
15
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.79
- -
60.49
Profit Margin (%)
-787.57
-1,391.71
-17,560.26
-4,930.18
-32.79
-120.22
-187.77
-102.6
-59.66
-75.4
-43.11
12.37
-32.45
0.75
Working Capital
235
211
162
298
1,140
1,252
1,204
2,069
2,151
1,938
1,926
2,342
1,443
1,617
LT Debt
2
4
15
6
425
421
730
1,073
1,138
1,602
1,273
1,330
1,028
895
Total Equity
247
248
190
337
789
1,032
818
762
928
385
859
1,528
1,141
1,529
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.63
- -
-0.75
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.82
- -
1.89
Return on Common Equity (%)
-60.39
-54.88
-100.47
-101.42
-9
-39.74
-77.29
-70.15
-49.57
-107.16
-86.15
19.71
-53.47
1.04

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
158
LT Borrowings
838
848
699
LT Finance Leases
199
198
196
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
106
106
107
Market Capitalization
2,294
1,902
1,962

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,310
2,224
2,273
Cash, Cash Equivalents & STI
653
788
879
Accounts Receivable, Net
395
377
369
Inventories
1,001
904
876
Total Current Liabilities
499
503
656
Payables & Accruals
226
217
213
ST Debt
- -
- -
158
Deferred Revenue
116
110
105

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
35.34%
27.79%
-25.34%
Free Cash Flow
-197.53%
-405.58%
-10.61%
Net Income, GAAP
10.21%
-105.48%
-403.27%
Sales/Revenue/Turnover
341.2%
32.94%
15.58%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
413
363
467
658
1,902
2025
745
611
399
443
2,198
2026
731
401
381
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.38
0.07
0.35
1.65
2.47
2025
-4.6
2.01
-0.5
-2.7
-7.13
2026
3.15
-0.05
-0.27
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Michael E. Severino
Full Time Employees
835
Sector
Health technology
Industry
Pharmaceuticals: major
Address
215 First Street Cambridge MA United States 02142
IPO Date
Jun 4, 1997
Business
Sarepta Therapeutics, Inc. (SRPT) is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare neuromuscular and central nervous system disorders, primarily Duchenne muscular dystrophy (DMD); its core products include FDA-approved RNA-targeted exon-skipping therapies EXONDYS 51 (eteplirsen) for exon 51 skipping, VYONDYS 53 (golodirsen) for exon 53 skipping, and AMONDYS 45 (casimersen) for exon 45 skipping, alongside the gene therapy ELEVIDYS (delandistrogene moxeparvovec-rokl) for DMD patients aged four and older with confirmed DMD gene mutations. The company advances a pipeline of over 40 programs across gene therapy, RNA technology including Morpholino oligomers and siRNA, and gene editing platforms, targeting DMD, limb-girdle muscular dystrophies (LGMDs), myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), Huntington's disease, and other rare diseases; it serves patients, healthcare providers, and partners globally through manufacturing facilities and commercialization efforts. Founded in 1980 and headquartered in Cambridge, Massachusetts, with operations including a Genetic Therapies Center of Excellence in Columbus, Ohio, Sarepta targets pediatric and adult patients in the U.S. and select international markets via collaborations such as ex-U.S. rights with Roche. Recent developments include a November 2024 global licensing and collaboration agreement with Arrowhead Pharmaceuticals, providing Sarepta four clinical-stage siRNA programs for DM1, FSHD, and other neuromuscular indications plus three preclinical assets for $500 million upfront, $325 million in Arrowhead equity, and $50 million annual payments over five years, which closed in February 2025 and advanced with a $100 million milestone for the SRP-1003 DM1 program in August 2025. In June 2024, the FDA expanded ELEVIDYS approval to ambulatory and non-ambulatory DMD patients aged four and older, granting traditional approval for non-ambulatory use and accelerated approval for ambulatory; confirmatory ESSENCE study data for additional exon-skipping therapies was completed in Q3 2025, supporting planned supplemental NDA filings. Amid challenges including patient deaths linked to ELEVIDYS prompting a July 2025 restructuring with 36% workforce layoffs for $400 million in 2026 cost savings, and FDA clearance in November 2025 for a study mitigating liver injury risks, Sarepta reported Q3 2025 revenues boosted by $166.9 million in collaboration income from Roche-related milestones and Japanese approvals.

Company News

  • Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: Cloudflare, Deckers Outdoors, DraftKings, MongoDB, Nike, Oneok, Philip Morris International, Riot Platforms, Wix.com, and More

  • Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance

  • Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript

  • SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline

  • Sarepta Therapeutics Q3 Earnings Call Highlights

  • Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics

  • Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

  • Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?

  • Sarepta Therapeutics to Present at Upcoming Investor Conferences

  • Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

  • Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)

  • Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

  • Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner'

  • Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

  • Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwright

  • Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

  • Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

  • Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

  • Squarepoint Ops LLC Has $1.51 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT